Drug intelligence / Profile preview

FPX004

Development stage: Preclinical
Lead developer: Guangdong Fapon Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FPX004 is a monoclonal antibody (mAb) being developed by Guangdong Fapon Biopharma for the treatment of cancer. It is a candidate within the company's oncology pipeline, which focuses on innovative biologics including therapeutic antibodies and fusion proteins. As of current public information, the specific antigen target and detailed mechanism of action for FPX004 have not been disclosed, and the drug is in the early stages of development.

Beyond the preview

Go deeper on FPX004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPX004.

Explore the full profile